Guardant Health shares plunged 27% after it released disappointing blood test results - Silicon Valley Business Journal

Dec 16, 2022, 4:32pm PST

The results indicate Guardant's test won't be an adequate substitute for colonoscopies or Cologuard, a screening that looks for signs of cancer in patients' stool, Jeffries analyst Brandon Couillard told Bloomberg. Cologuard maker Exact Sciences Inc. says its test is 92% accurate at detecting colon cancer., down $11.20 a piece. Earlier in the session, its shares were down as much as $13.51, or 32%.

Österreich Neuesten Nachrichten, Österreich Schlagzeilen